Trending Now
Aslan Pharmaceuticals Ltd (NASDAQ:ASLN) Kicks Off Third Dose Cohort In Its...
Aslan Pharmaceuticals Ltd (NASDAQ:ASLN) recently announced the shift to the third dose cohort of its developmental atopic dermatitis treatment called ASLAN004 as part of...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Dose First Patient In Selinexor Study In...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has announced that it has dosed the first patient in its Phase 1/2 clinical trial for the evaluation of oral...
MAKE IT MODERN
LATEST REVIEWS
BioNTech (NASDAQ:BNTX) Says Its COVID-19 Vaccine With Pfizer (NYSE:PFE) Will Not...
BioNTech (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) have joined other leading coronavirus vaccine developers in opting out of participation in the UK plans of testing...
MAKE IT MODERN
PERFORMANCE TRAINING
Merck and Co Inc. (NYSE: MRK) Plans To Acquired Acceleron Pharma Inc. (NASDAQ: XLRN)...
Merck and Co Inc. (NYSE: MRK) is in advanced negotiations to purchase Acceleron Pharma Inc. (NASDAQ: XLRN) in a move that will...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) Posts Net Product Revenue Of $121.4 Million In Q3 2020
Sarepta Therapeutics Inc. (NASDAQ:SRPT) has announced its Q3 2020 financial results with net product sales up 23% YoY to $121.4 million.
Sarepta reports 23% YoY...
The USPTO Grants An Innovative Composition Of Matter Patent To Alterity Therapeutics Ltd (NASDAQ:...
Alterity Therapeutics Ltd (NASDAQ: ATHE) received a new patent from the USPTO (The United States Patent and Trademark Office).
With this new patent, Alterity can...
Alzamend Neuro Inc (NASDAQ: ALZN) is granted FDA Approval for the Phase I Clinical...
Alzamend Neuro Inc (NASDAQ: ALZN) is a clinical-stage biopharma corporation that concentrates on developing novel medicare products that can be used to treat mental disorders...
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Planning To Complete Phase 3 RELIEF TNX-102 SL study...
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced results of the pre-planned provisional analysis of the third phase RELIEF trial of cyclobenzaprine HCI sublingual tablets...
MAKE IT MODERN
